## 510K Summary

Stryker Spine - LITe® Decompression System - Light Cable Traditional 510(k) Premarket Notification

K122637

510(k) Summary of Safety and Effectiveness Stryker Spine - LITe® Decompression System - Light Cable

NOV 1 2012

Stryker Spine ,	
2 Pearl Court	
Allendale, New Jersey 07401	
Ms. Tina Mornak	
Regulatory Affairs Associate	
Phone: 201-760-8193	
Fax: 201-962-4193	
Email: tina.mornak@stryker.com	
October 25, 2012	
Stryker Spine - LITe® Decompression System - Light Cable	
Class II	
Light, Surgical, Fiber optic	
21 CFR 878.4580	
Surgical lamp	
FST	
NuVasive MaXcess Light Guide: K042034	
Zimmer MIS Light: K080367	
The Stryker Spine LITe® Decompression System - Light Cable is a	
single use, sterile and disposable component. The Stryker Spine LITe®	
Decompression System - Light Cable consists of fiber optic cables	
contained within silicone tubing which can be connected to a light	
generator on one end and the tube of the Stryker Spine LITe®	
Decompression System on the other end.	
The Stryker Spine LITe® Decompression System - Light Cable is	
intended to provide surgical site illumination from a high intensity	
light source when Stryker decompression tubes are in use.	
The LITe® Decompression System – Light Cable shares the same	
technological characteristics as the predicate devices. These	
characteristics include similar design, technical requirements,	
materials and intended use.	





Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

Stryker Spine % Ms. Tina Mornak Regulatory Affairs Associate 2 Pearl Court Allendale, New Jersey 07401

NOV

1 2012

Re: K122637

Trade/Device Name: Stryker LITe ® Decompression System-Light Cable

Regulation Number: 21 CFR 878.4580

Regulation Name: Surgical lamp

Regulatory Class: Class II

Product Code: FST Dated: August 23, 2012 Received: August 29, 2012

Dear Ms. Mornak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Peter D. Rumm -S 2012.11.05 10:44:24 -05'00'

> Mark N. Melkerson Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

## Indications for Use

ndications for Use:	
	n - Light Cable is intended to provide surgical sit
lumination from a high intensity light source	when Stryker decompression tubes are in use.
•	
•	
. •	
•	
	•
2.1	Λ.
MilROS	de for nom
(Division Sign-Ofi)	
Division of Surgical	
and Restorative Dev	vices
610(1)	4122637
510(k) Number	
rescription Use X AND/OR	Over-The-Counter Use (21 CFR 807 Subpart C)
Part 21 CFR 801 Subpart D)	(21 01 11 001 0 dbpair 0)
(PLEASE DO NOT WRITE BELOW THIS I	INE-CONTINUE ON ANOTHER PAGE IF NEED
( LE IOL BO NOT MINITE BELOW THIS	